TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38839381

Group type: EXPERIMENTAL
Intervention: TROD Screen questionnaire for HIV infection
Number of subjects: 15343

Group type: EXPERIMENTAL
Intervention: TROD Screen questionnaire for HBV infection in men
Number of subjects: 15343

Group type: EXPERIMENTAL
Intervention: TROD Screen questionnaire for HBV infection in women
Number of subjects: 15343

Group type: EXPERIMENTAL
Intervention: TROD Screen questionnaire for HCV infection
Number of subjects: 15343
Study: 38839388

Group type: EXPERIMENTAL
Intervention: IOP-lowering eyedrops (intervention group)
Number of subjects: 152

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 152
Study: 38839392

Group type: EXPERIMENTAL
Intervention: Contraceptive counselling package (arm 2)
Number of subjects: 7920

Group type: EXPERIMENTAL
Intervention: Contraceptive counselling package combined with wider methods availability (arm 3)
Number of subjects: 7920

Group type: COMPARATOR
Intervention: Routine care (arm 1)
Number of subjects: 7920
Study: 38839505

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks until disease progression or unacceptable toxicity
Number of subjects: 1004
Study: 38839899

Group type: EXPERIMENTAL
Intervention: Dazodalibep (DAZ)
Number of subjects: 183
Study: 38840084

Group type: EXPERIMENTAL
Intervention: MyBack programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 38840086

Group type: COMPARATOR
Intervention: Standard CDC information about HPV vaccination (Control)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Video narratives about HPV vaccination
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Written narratives about HPV vaccination
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Enhanced access to HPV vaccine + Standard CDC information
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Enhanced access to HPV vaccine + Video narratives
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Enhanced access to HPV vaccine + Written narratives
Number of subjects: 1200
Study: 38840160

Group type: EXPERIMENTAL
Intervention: Collaborative decision skills training (CDST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0
Study: 38840166

Group type: EXPERIMENTAL
Intervention: High baseline CRP (>3 mg/L)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High baseline IL-6
Number of subjects: 200
Study: 38840210

Group type: EXPERIMENTAL
Intervention: Low inhaled concentration of desflurane (0.5 MAC) combined with propofol and remifentanil
Number of subjects: 70

Group type: COMPARATOR
Intervention: High inhaled concentration of desflurane (0.7-1.0 MAC) combined with remifentanil
Number of subjects: 70
Study: 38840219

Group type: EXPERIMENTAL
Intervention: JAK inhibitors (baricitinib, n=15; tofacitinib, n=10; upadacitinib, n=10)
Number of subjects: 35
Study: 38840410

Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 195

Group type: COMPARATOR
Intervention: cIVF
Number of subjects: 195
Study: 38840578

Group type: EXPERIMENTAL
Intervention: Hyperaemic stenosis resistance (HSR) index
Number of subjects: 853
Study: 38840580

Group type: EXPERIMENTAL
Intervention: Presence of OCT vulnerability features (OCT-VFs) including TCFA, r-MLA, HP, and CP
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: TCFA alone
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Coexistence of TCFA with other OCT-VFs
Number of subjects: 491
Study: 38840973

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 0
Study: 38841077

Group type: EXPERIMENTAL
Intervention: Acupuncture intervention
Number of subjects: 79
Study: 38841123

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) intervention
Number of subjects: 0
Study: 38841377

Group type: EXPERIMENTAL
Intervention: Self-reported methods (SRMs) including Morisky-Green test (MGT) and Batalla test (BT)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Reference method (RM) - pill count
Number of subjects: 387
Study: 38841588

Group type: EXPERIMENTAL
Intervention: Colchicine (MACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DAPT (Dual Antiplatelet Therapy)
Number of subjects: 0
Study: 38841694

Group type: EXPERIMENTAL
Intervention: Haploidentical stem cell transplantation (HISCT)
Number of subjects: 19
Study: 38841781

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1000 mg twice daily on D1-D10 + Etoposide 200 mg on D2-D8
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg twice daily on D1-D10 + Etoposide 200 mg on D2-D8
Number of subjects: 11
Study: 38841799

Group type: EXPERIMENTAL
Intervention: Baseline post-bronchodilator (post-BD) spirometry measures of lung function
Number of subjects: 11181

Group type: EXPERIMENTAL
Intervention: COPD only
Number of subjects: 11181
Study: 38841854

Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 2895

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 2895
Study: 38841856

Group type: EXPERIMENTAL
Intervention: High-intensity statin therapy
Number of subjects: 0
Study: 38842053

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: BCG plus MMC
Number of subjects: 72
Study: 38842100

Group type: EXPERIMENTAL
Intervention: High VPA (≥1 session/week)
Number of subjects: 0
Study: 38842286

Group type: EXPERIMENTAL
Intervention: Self-performed sodium reduction diet
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 38842323

Group type: EXPERIMENTAL
Intervention: BPaL (bedaquiline, pretomanid, and linezolid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BPaLC (BPaL with clofazimine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BPaLM (BPaL with moxifloxacin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age, body mass index, and country
Number of subjects: 0
Study: 38842347

Group type: EXPERIMENTAL
Intervention: CLN-617 (intratumoral injection of a single-chain fusion protein comprising IL2 and IL12)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CLN-617
Number of subjects: 0
Study: 38842448

Group type: EXPERIMENTAL
Intervention: Standard dose DOAC
Number of subjects: 1657

Group type: EXPERIMENTAL
Intervention: Low dose DOAC
Number of subjects: 1657

Group type: EXPERIMENTAL
Intervention: High C-trough standardized values (>0.50)
Number of subjects: 1657

Group type: EXPERIMENTAL
Intervention: Lower C-trough standardized values (≤0.50)
Number of subjects: 1657

Group type: EXPERIMENTAL
Intervention: Low-dose DOAC use
Number of subjects: 1657
Study: 38842520

Group type: COMPARATOR
Intervention: Peginterferon alfa-2a alone (180 μg per week for 48 weeks)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: 2 mg bulevirtide plus peginterferon alfa-2a (180 μg per week for 48 weeks)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: 10 mg bulevirtide plus peginterferon alfa-2a (180 μg per week for 48 weeks)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: 10 mg bulevirtide monotherapy (for 96 weeks)
Number of subjects: 174
Study: 38842606

Group type: EXPERIMENTAL
Intervention: Neoadjuvant-adjuvant anti-PD1 therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant anti-PD-1 therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored approach to surgery and adjuvant therapy based on response to initial neoadjuvant immunotherapy
Number of subjects: 0
Study: 38842738

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied on days 0, 3, 7, and 14 after extraction, repeated biweekly until the end of retraction.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonlaser group (NLG) without LLLT application.
Number of subjects: 36
Study: 38842764

Group type: EXPERIMENTAL
Intervention: Dexketoprofen 25 mg/vitamin B (thiamine 100 mg, pyridoxine 50 mg, cyanocobalamin 0.50 mg) in a fixed-dose combination (FDC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexketoprofen 25 mg monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FDC of dexketoprofen/thiamine + pyridoxine + cyanocobalamin vitamins
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexketoprofen monotherapy
Number of subjects: 0
Study: 38842799

Group type: EXPERIMENTAL
Intervention: NCM plus HBPTM (20 counseling calls over 12 months); n=224
Number of subjects: 450

Group type: COMPARATOR
Intervention: HBPTM alone (12 home BP measurements/week for 12 months); n=226
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: NCM plus HBPTM
Number of subjects: 450

Group type: COMPARATOR
Intervention: HBPTM alone
Number of subjects: 450
Study: 38842838

Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab plus chemotherapy (nab-paclitaxel and carboplatin) followed by response-adapted locoregional therapy (LRT)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Response-adapted therapy (group A: single-modality radiotherapy or transoral robotic surgery; group B: intermediate-dose chemoradiotherapy; group C: regular-dose chemoradiotherapy)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab and chemotherapy followed by response-adapted LRT
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 77
Study: 38842850

Group type: EXPERIMENTAL
Intervention: mHealth intervention (cognitive behavior therapy for psychosis strategies)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison app (mobile assessment plus psychoeducation)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (mHealth intervention and comparison app)
Number of subjects: 42
Study: 38842930

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (web-delivered PA intervention with text messages and additional features)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Original intervention (Spanish-language, individually tailored, web-delivered PA intervention)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Enhanced intervention for low-active participants
Number of subjects: 195

Group type: COMPARATOR
Intervention: Original intervention for low-active participants
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Enhanced intervention for inactive participants
Number of subjects: 195

Group type: COMPARATOR
Intervention: Original intervention for inactive participants
Number of subjects: 195
Study: 38842955

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM) therapy
Number of subjects: 85
Study: 38842956

Group type: EXPERIMENTAL
Intervention: intermittent TBS (iTBS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: continuous TBS (cTBS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: active control cTBS
Number of subjects: 15
Study: 38842957

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 13492
Study: 38842972

Group type: EXPERIMENTAL
Intervention: PVI + EGF-guided ablation
Number of subjects: 85

Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 85
Study: 38842991

Group type: EXPERIMENTAL
Intervention: IVUS-guided DCB angioplasty
Number of subjects: 260

Group type: COMPARATOR
Intervention: Angiography-guided DCB angioplasty
Number of subjects: 260
Study: 38843038

Group type: EXPERIMENTAL
Intervention: Clusters based on within-treatment symptom trajectories
Number of subjects: 0
Study: 38843105

Group type: EXPERIMENTAL
Intervention: Bexotegrast, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 38843149

Group type: EXPERIMENTAL
Intervention: mISP combined with MINDBODYSTRONG© program
Number of subjects: 364

Group type: COMPARATOR
Intervention: mISP alone
Number of subjects: 364
Study: 38843234

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (150 minutes per week at moderate-to-vigorous intensity for 28 weeks)
Number of subjects: 34
Study: 38843267

Group type: EXPERIMENTAL
Intervention: 15 μg H1N1 influenza vaccine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 7.5 μg H1N1 influenza vaccine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both VX-103 dose groups
Number of subjects: 45
Study: 38843272

Group type: EXPERIMENTAL
Intervention: pool-REST (weekly 1-hour float sessions)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: pool-REST preferred (flexible duration and frequency)
Number of subjects: 75

Group type: COMPARATOR
Intervention: chair-REST (weekly 1-hour sessions in a Zero Gravity chair)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 75
Study: 38843355

Group type: EXPERIMENTAL
Intervention: Ivosidenib (anti-IDH1 therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional chemotherapeutics
Number of subjects: 0
Study: 38843469

Group type: EXPERIMENTAL
Intervention: nal-IRI/FU/LV
Number of subjects: 91

Group type: COMPARATOR
Intervention: G/C
Number of subjects: 91
Study: 38843479

Group type: EXPERIMENTAL
Intervention: Scalp cooling
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control (usual clinical practice)
Number of subjects: 139
Study: 38843483

Group type: EXPERIMENTAL
Intervention: Deep learning-based algorithm for automated treatment response assessment according to the Lugano 2014 classification.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Deep learning-based algorithm for automated treatment response assessment.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Radiologist review of the algorithm's assessments.
Number of subjects: 3
Study: 38843488

Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin (Teliso-V)
Number of subjects: 172
Study: 38843489

Group type: EXPERIMENTAL
Intervention: Subscalp EEG
Number of subjects: 8
Study: 38843498

Group type: EXPERIMENTAL
Intervention: PRODIGY high risk group
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: PRODIGY intermediate risk group
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: PRODIGY low risk group
Number of subjects: 87

Group type: COMPARATOR
Intervention: Comparison of RDE rates
Number of subjects: 87
Study: 38843511

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) - 10 mg/kg intravenous infusion on days 1 and 8
Number of subjects: 603

Group type: COMPARATOR
Intervention: Docetaxel - 75 mg/m²
Number of subjects: 603
Study: 38843513

Group type: EXPERIMENTAL
Intervention: Web-based single-session Empowered Relief
Number of subjects: 45
Study: 38843595

Group type: EXPERIMENTAL
Intervention: AD + IID (30-min session)
Number of subjects: 17

Group type: COMPARATOR
Intervention: AD alone (30-min session)
Number of subjects: 17
Study: 38843604

Group type: EXPERIMENTAL
Intervention: Telephone assessment at 16 months
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Patients asymptomatic at four months
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Patients evaluated twice (4 months and 16 months)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Anxiety prevalence
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Lung CT-scan at 16 months
Number of subjects: 478
Study: 38843852

Group type: EXPERIMENTAL
Intervention: Cervical spine injury prediction rule applied to children with risk factors for cervical spine injury
Number of subjects: 22430

Group type: EXPERIMENTAL
Intervention: Clinical algorithm for determining which risk factors warrant radiographic screening
Number of subjects: 22430
Study: 38843856

Group type: EXPERIMENTAL
Intervention: 4 Gy radiotherapy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 20 Gy radiotherapy (for those with partial response)
Number of subjects: 24
Study: 38843860

Group type: EXPERIMENTAL
Intervention: Vimseltinib (30 mg orally twice weekly for 24 weeks)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Vimseltinib
Number of subjects: 123
Study: 38843950

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) administered into the large intestine (LI)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) administered into the small intestine (SI)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) administered into the small intestine (SI) twice (repeated SI)
Number of subjects: 171
Study: 38844004

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: FF/VI
Number of subjects: 0

Group type: COMPARATOR
Intervention: UMEC/VI
Number of subjects: 0
Study: 38844374

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 µg thrice daily for 2 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 38844401

Group type: EXPERIMENTAL
Intervention: Laser closure
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ligation of the intersphincteric fistula tract (LIFT)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 56
Study: 38844406

Group type: EXPERIMENTAL
Intervention: Blinatumomab (5 μg/m²)
Number of subjects: 177
Study: 38844468

Group type: EXPERIMENTAL
Intervention: penpulimab and anlotinib in combination with nab-paclitaxel/gemcitabine (PAAG)
Number of subjects: 66
Study: 38844602

Group type: EXPERIMENTAL
Intervention: Passive Leg Raising (PLR)
Number of subjects: 27
Study: 38844671

Group type: EXPERIMENTAL
Intervention: Weight Loss Maintenance 3 Phases Program (WLM3P)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Standard low-carbohydrate diet (LCD)
Number of subjects: 112
Study: 38844682

Group type: EXPERIMENTAL
Intervention: Guselkumab every 4 weeks (Q4W)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study: 38844793

Group type: EXPERIMENTAL
Intervention: Stimulation (auditory stimuli delivered at specific phases of participants' alpha oscillations for 30 minutes)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham (headband silently recorded EEG)
Number of subjects: 21
Study: 38844794

Group type: EXPERIMENTAL
Intervention: Intravesical cretostimogene with systemic pembrolizumab
Number of subjects: 35
Study: 38844796

Group type: EXPERIMENTAL
Intervention: Precision-guided treatment (PGT)
Number of subjects: 384
Study: 38844797

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard care or placebo)
Number of subjects: 0
Study: 38844798

Group type: EXPERIMENTAL
Intervention: Calibrated blood-collection drape for early detection of PPH and bundled first-response treatments (uterine massage, oxytocic drugs, tranexamic acid, intravenous fluids, examination and escalation)
Number of subjects: 210132

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210132
Study: 38844862

Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg daily for 10 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post-treatment observation
Number of subjects: 10
Study: 38844921

Group type: EXPERIMENTAL
Intervention: Dual systemic anti-pseudomonal antibiotics for 14 days
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no antibiotic treatment)
Number of subjects: 49
Study: 38844941

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg or 10 mg)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study: 38844992

Group type: EXPERIMENTAL
Intervention: TASKPEN multifaceted implementation strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38845045

Group type: EXPERIMENTAL
Intervention: VHW-led lifestyle counseling and guideline-directed antihypertensive, lipid-lowering, and antiplatelet treatment supported by a tablet-based decision support application in intervention villages.
Number of subjects: 1447

Group type: COMPARATOR
Intervention: Control group referred to a health facility for therapeutic management.
Number of subjects: 1447
Study: 38845046

Group type: EXPERIMENTAL
Intervention: PF-06835375 (dose range: 0.03-6 mg) - single doses administered intravenously
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: PF-06835375 (dose range: 0.3-10 mg) - repeat doses administered subcutaneously on Days 1 and 29
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 38845066

Group type: EXPERIMENTAL
Intervention: Potentially cardiotoxic chemotherapy (doxorubicin, cyclophosphamide, paclitaxel, trastuzumab)
Number of subjects: 210
Study: 38845164

Group type: EXPERIMENTAL
Intervention: FIT cut-off 20 µg/g
Number of subjects: 3841

Group type: EXPERIMENTAL
Intervention: FIT cut-off 40 µg/g
Number of subjects: 3841

Group type: COMPARATOR
Intervention: FIT cut-off 10 µg/g
Number of subjects: 3841

Group type: EXPERIMENTAL
Intervention: FIT cut-off 20 µg/g (men)
Number of subjects: 3841

Group type: EXPERIMENTAL
Intervention: FIT cut-off 20 µg/g (women)
Number of subjects: 3841
Study: 38845167

Group type: EXPERIMENTAL
Intervention: Plasma YKL-40 concentration measured before EVT
Number of subjects: 120
Study: 38845180

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT) plus best medical management
Number of subjects: 530

Group type: COMPARATOR
Intervention: Best medical management only
Number of subjects: 530
Study: 38845190

Group type: EXPERIMENTAL
Intervention: DUOSTIM fresh (double stimulation)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Single stimulation (control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: DUOSTIM fresh (luteal-phase)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: DUOSTIM fresh (follicular-phase)
Number of subjects: 120
Study: 38845288

Group type: EXPERIMENTAL
Intervention: Optimal treatment of traditional cardiovascular risk factors
Number of subjects: 15773

Group type: COMPARATOR
Intervention: Prior cardiovascular disease (CVD)
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Number of risk factors outside target
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Overtreated patients (haemoglobin A1c)
Number of subjects: 15773
Study: 38846367

Group type: EXPERIMENTAL
Intervention: team-based virtual care
Number of subjects: 64

Group type: COMPARATOR
Intervention: in-person physical therapist assessment
Number of subjects: 64

Group type: COMPARATOR
Intervention: nurse practitioner care
Number of subjects: 64
Study: 38846444

Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW) intervention for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cardiological counseling (control group)
Number of subjects: 0
Study: 38846451

Group type: EXPERIMENTAL
Intervention: PBP + Leu
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WHEY
Number of subjects: 0

Group type: COMPARATOR
Intervention: PBP
Number of subjects: 0
Study: 38846687

Group type: EXPERIMENTAL
Intervention: NTCI (cSN50.1 peptide)
Number of subjects: 0